Global Markets Direct’s, ‘Ovarian Cancer – Pipeline Review, H2 2015′, provides an overview of the Ovarian Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ovarian Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides a snapshot of the global therapeutic landscape of Ovarian Cancer
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Ovarian Cancer and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Ovarian Cancer pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products

Reasons to buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Ovarian Cancer
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Ovarian Cancer pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
Introduction 12
Ovarian Cancer Overview 13
Therapeutics Development 14
Ovarian Cancer - Therapeutics under Development by Companies 16
Ovarian Cancer - Therapeutics under Investigation by Universities/Institutes 38
Ovarian Cancer - Pipeline Products Glance 41
Ovarian Cancer - Products under Development by Companies 44
Ovarian Cancer - Products under Investigation by Universities/Institutes 72
Ovarian Cancer - Companies Involved in Therapeutics Development 76
Ovarian Cancer - Therapeutics Assessment 334
Drug Profiles 378
Ovarian Cancer - Recent Pipeline Updates 1165
Ovarian Cancer - Dormant Projects 1608
Ovarian Cancer - Discontinued Products 1633
Ovarian Cancer - Product Development Milestones 1639
Appendix 1647

List of Tables

Number of Products under Development for Ovarian Cancer, H2 2015 64
Number of Products under Development for Ovarian Cancer - Comparative Analysis, H2 2015 65
Number of Products under Development by Companies, H2 2015 67
Number of Products under Development by Companies, H2 2015 (Contd..1) 68
Number of Products under Development by Companies, H2 2015 (Contd..2) 69
Number of Products under Development by Companies, H2 2015 (Contd..3) 70
Number of Products under Development by Companies, H2 2015 (Contd..4) 71
Number of Products under Development by Companies, H2 2015 (Contd..5) 72
Number of Products under Development by Companies, H2 2015 (Contd..6) 73
Number of Products under Development by Companies, H2 2015 (Contd..7) 74
Number of Products under Development by Companies, H2 2015 (Contd..8) 75
Number of Products under Development by Companies, H2 2015 (Contd..9) 76
Number of Products under Development by Companies, H2 2015 (Contd..10) 77
Number of Products under Development by Companies, H2 2015 (Contd..11) 78
Number of Products under Development by Companies, H2 2015 (Contd..12) 79
Number of Products under Development by Companies, H2 2015 (Contd..13) 80
Number of Products under Development by Companies, H2 2015 (Contd..14) 81
Number of Products under Development by Companies, H2 2015 (Contd..15) 82
Number of Products under Development by Companies, H2 2015 (Contd..16) 83
Number of Products under Development by Companies, H2 2015 (Contd..17) 84
Number of Products under Development by Companies, H2 2015 (Contd..18) 85
Number of Products under Development by Companies, H2 2015 (Contd..19) 86
Number of Products under Development by Companies, H2 2015 (Contd..20) 87
Number of Products under Investigation by Universities/Institutes, H2 2015 88
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 89
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..2) 90
Comparative Analysis by Late Stage Development, H2 2015 91
Comparative Analysis by Clinical Stage Development, H2 2015 92
Comparative Analysis by Early Stage Development, H2 2015 93
Products under Development by Companies, H2 2015 94
Products under Development by Companies, H2 2015 (Contd..1) 95
Products under Development by Companies, H2 2015 (Contd..2) 96
Products under Development by Companies, H2 2015 (Contd..3) 97
Products under Development by Companies, H2 2015 (Contd..4) 98
Products under Development by Companies, H2 2015 (Contd..5) 99
Products under Development by Companies, H2 2015 (Contd..6) 100
Products under Development by Companies, H2 2015 (Contd..7) 101
Products under Development by Companies, H2 2015 (Contd..8) 102
Products under Development by Companies, H2 2015 (Contd..9) 103
Products under Development by Companies, H2 2015 (Contd..10) 104
Products under Development by Companies, H2 2015 (Contd..11) 105
Products under Development by Companies, H2 2015 (Contd..12) 106
Products under Development by Companies, H2 2015 (Contd..13) 107
Products under Development by Companies, H2 2015 (Contd..14) 108
Products under Development by Companies, H2 2015 (Contd..15) 109
Products under Development by Companies, H2 2015 (Contd..16) 110
Products under Development by Companies, H2 2015 (Contd..17) 111
Products under Development by Companies, H2 2015 (Contd..18) 112
Products under Development by Companies, H2 2015 (Contd..19) 113
Products under Development by Companies, H2 2015 (Contd..20) 114
Products under Development by Companies, H2 2015 (Contd..21) 115
Products under Development by Companies, H2 2015 (Contd..22) 116
Products under Development by Companies, H2 2015 (Contd..23) 117
Products under Development by Companies, H2 2015 (Contd..24) 118
Products under Development by Companies, H2 2015 (Contd..25) 119
Products under Development by Companies, H2 2015 (Contd..26) 120
Products under Development by Companies, H2 2015 (Contd..27) 121
Products under Investigation by Universities/Institutes, H2 2015 122
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 123
Products under Investigation by Universities/Institutes, H2 2015 (Contd..2) 124
Products under Investigation by Universities/Institutes, H2 2015 (Contd..3) 125
Ovarian Cancer - Pipeline by 3-V Biosciences, Inc., H2 2015 126
Ovarian Cancer - Pipeline by 4SC AG, H2 2015 127
Ovarian Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2015 128
Ovarian Cancer - Pipeline by AB Science SA, H2 2015 129
Ovarian Cancer - Pipeline by AbbVie Inc., H2 2015 130
Ovarian Cancer - Pipeline by Abeona Therapeutics, Inc. , H2 2015 131
Ovarian Cancer - Pipeline by AbGenomics International, Inc., H2 2015 132
Ovarian Cancer - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2015 133
Ovarian Cancer - Pipeline by Adaptimmune Limited, H2 2015 134
Ovarian Cancer - Pipeline by Aduro BioTech, Inc., H2 2015 135
Ovarian Cancer - Pipeline by Advanced Accelerator Applications SA, H2 2015 136
Ovarian Cancer - Pipeline by Advantagene, Inc., H2 2015 137
Ovarian Cancer - Pipeline by Advaxis, Inc., H2 2015 138
Ovarian Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2015 139
Ovarian Cancer - Pipeline by Aeterna Zentaris Inc., H2 2015 140
Ovarian Cancer - Pipeline by Agilvax, Inc., H2 2015 141
Ovarian Cancer - Pipeline by Alchemia Limited, H2 2015 142
Ovarian Cancer - Pipeline by Alethia Biotherapeutics Inc., H2 2015 143
Ovarian Cancer - Pipeline by Almac Discovery Limited, H2 2015 144
Ovarian Cancer - Pipeline by Ambrx, Inc., H2 2015 145
Ovarian Cancer - Pipeline by Amgen Inc., H2 2015 146
Ovarian Cancer - Pipeline by Anavex Life Sciences Corp., H2 2015 147
Ovarian Cancer - Pipeline by ANP Technologies, Inc., H2 2015 148
Ovarian Cancer - Pipeline by Antoxis Limited, H2 2015 149
Ovarian Cancer - Pipeline by Aphios Corporation, H2 2015 150
Ovarian Cancer - Pipeline by Aposense Ltd., H2 2015 151
Ovarian Cancer - Pipeline by Aprea AB, H2 2015 152
Ovarian Cancer - Pipeline by arGEN-X BV, H2 2015 153
Ovarian Cancer - Pipeline by Armour Therapeutics Inc., H2 2015 154
Ovarian Cancer - Pipeline by Arog Pharmaceuticals, Inc., H2 2015 155
Ovarian Cancer - Pipeline by ArQule, Inc., H2 2015 156
Ovarian Cancer - Pipeline by Array BioPharma Inc., H2 2015 157
Ovarian Cancer - Pipeline by Arrien Pharmaceuticals, LLC, H2 2015 158
Ovarian Cancer - Pipeline by Ascenta Therapeutics, Inc., H2 2015 159
Ovarian Cancer - Pipeline by Astellas Pharma Inc., H2 2015 160
Ovarian Cancer - Pipeline by Astex Pharmaceuticals, Inc., H2 2015 161
Ovarian Cancer - Pipeline by AstraZeneca Plc, H2 2015 162
Ovarian Cancer - Pipeline by Atara Biotherapeutics, Inc., H2 2015 163
Ovarian Cancer - Pipeline by ATLAB Pharma SAS, H2 2015 164
Ovarian Cancer - Pipeline by AVAX Technologies, Inc., H2 2015 165
Ovarian Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015 166
Ovarian Cancer - Pipeline by Avipep Pty Ltd, H2 2015 167
Ovarian Cancer - Pipeline by Azaya Therapeutics, Inc., H2 2015 168
Ovarian Cancer - Pipeline by Basilea Pharmaceutica AG, H2 2015 169
Ovarian Cancer - Pipeline by Bavarian Nordic A/S, H2 2015 170
Ovarian Cancer - Pipeline by Bayer AG, H2 2015 171
Ovarian Cancer - Pipeline by BeiGene(Beijing) Co.,Ltd, H2 2015 172
Ovarian Cancer - Pipeline by Beth Israel Deaconess Medical Center, Inc., H2 2015 173
Ovarian Cancer - Pipeline by BioAtla, LLC, H2 2015 174
Ovarian Cancer - Pipeline by BioCancell Ltd, H2 2015 175
Ovarian Cancer - Pipeline by BioMoti Limited, H2 2015 176
Ovarian Cancer - Pipeline by Bionomics Limited, H2 2015 177
Ovarian Cancer - Pipeline by BioNumerik Pharmaceuticals, Inc., H2 2015 178
Ovarian Cancer - Pipeline by Bioo Therapeutics, H2 2015 179
Ovarian Cancer - Pipeline by Biscayne Pharmaceuticals, Inc., H2 2015 180
Ovarian Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2015 181
Ovarian Cancer - Pipeline by Boston Biomedical, Inc., H2 2015 182
Ovarian Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2015 183
Ovarian Cancer - Pipeline by Caladrius Biosciences, Inc. , H2 2015 184
Ovarian Cancer - Pipeline by Calithera Biosciences, Inc., H2 2015 185
Ovarian Cancer - Pipeline by CASI Pharmaceuticals Inc., H2 2015 186
Ovarian Cancer - Pipeline by Cavion LLC, H2 2015 187
Ovarian Cancer - Pipeline by cCAM Biotherapeutics Ltd., H2 2015 188
Ovarian Cancer - Pipeline by Cellceutix Corporation, H2 2015 189
Ovarian Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2015 190
Ovarian Cancer - Pipeline by Cellectar Biosciences, Inc., H2 2015 191
Ovarian Cancer - Pipeline by Cellular Biomedicine Group, Inc., H2 2015 192
Ovarian Cancer - Pipeline by Celon Pharma Sp. z o.o., H2 2015 193
Ovarian Cancer - Pipeline by Celsion Corporation, H2 2015 194
Ovarian Cancer - Pipeline by Celyad SA, H2 2015 195
Ovarian Cancer - Pipeline by Ceronco Biosciences, H2 2015 196
Ovarian Cancer - Pipeline by Cerulean Pharma, Inc., H2 2015 197
Ovarian Cancer - Pipeline by Chikujee Therapeutics, H2 2015 198
Ovarian Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2015 199
Ovarian Cancer - Pipeline by Clevexel Pharma SAS, H2 2015 200
Ovarian Cancer - Pipeline by Clovis Oncology, Inc., H2 2015 201
Ovarian Cancer - Pipeline by CohBar, Inc., H2 2015 202
Ovarian Cancer - Pipeline by Commence Bio, Inc., H2 2015 203
Ovarian Cancer - Pipeline by Compliment Corporation, H2 2015 204
Ovarian Cancer - Pipeline by Critical Outcome Technologies Inc., H2 2015 205
Ovarian Cancer - Pipeline by CritiTech, Inc., H2 2015 206
Ovarian Cancer - Pipeline by CTI BioPharma Corp., H2 2015 207
Ovarian Cancer - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2015 208
Ovarian Cancer - Pipeline by CytRx Corporation, H2 2015 209
Ovarian Cancer - Pipeline by CZ BioMed Corp, H2 2015 210
Ovarian Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2015 211
Ovarian Cancer - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2015 212
Ovarian Cancer - Pipeline by DEKK-TEC, Inc., H2 2015 213
Ovarian Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H2 2015 214
Ovarian Cancer - Pipeline by EirGenix Inc., H2 2015 215
Ovarian Cancer - Pipeline by Eisai Co., Ltd., H2 2015 216
Ovarian Cancer - Pipeline by Eli Lilly and Company, H2 2015 217
Ovarian Cancer - Pipeline by Endocyte, Inc., H2 2015 218
Ovarian Cancer - Pipeline by EntreChem, S.L., H2 2015 219
Ovarian Cancer - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015 220
Ovarian Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H2 2015 221
Ovarian Cancer - Pipeline by Exelixis, Inc., H2 2015 222
Ovarian Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 223
Ovarian Cancer - Pipeline by Fortress Biotech, Inc., H2 2015 224
Ovarian Cancer - Pipeline by Fujifilm Corporation, H2 2015 225
Ovarian Cancer - Pipeline by Galena Biopharma, Inc., H2 2015 226
Ovarian Cancer - Pipeline by Galileo Research s.r.l., H2 2015 227
Ovarian Cancer - Pipeline by GamaMabs Pharma S.A., H2 2015 228
Ovarian Cancer - Pipeline by Ganymed Pharmaceuticals AG, H2 2015 229
Ovarian Cancer - Pipeline by Genentech, Inc., H2 2015 230
Ovarian Cancer - Pipeline by Generex Biotechnology Corporation, H2 2015 231
Ovarian Cancer - Pipeline by Genmab A/S, H2 2015 232
Ovarian Cancer - Pipeline by Genor BioPharma Co., Ltd., H2 2015 233
Ovarian Cancer - Pipeline by GlaxoSmithKline Plc, H2 2015 234
Ovarian Cancer - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2015 235
Ovarian Cancer - Pipeline by GlycoNex Inc., H2 2015 236
Ovarian Cancer - Pipeline by Glycotope GmbH, H2 2015 237
Ovarian Cancer - Pipeline by GP Pharm, S.A., H2 2015 238
Ovarian Cancer - Pipeline by Gradalis Inc., H2 2015 239
Ovarian Cancer - Pipeline by Halozyme Therapeutics, Inc., H2 2015 240
Ovarian Cancer - Pipeline by Heat Biologics, Inc., H2 2015 241
Ovarian Cancer - Pipeline by HEC Pharm Co., Ltd., H2 2015 242
Ovarian Cancer - Pipeline by Hemispherx Biopharma, Inc., H2 2015 243
Ovarian Cancer - Pipeline by Horizon Pharma Plc, H2 2015 244
Ovarian Cancer - Pipeline by Huabo Biopharm Co., Ltd., H2 2015 245
Ovarian Cancer - Pipeline by Ignyta, Inc., H2 2015 246
Ovarian Cancer - Pipeline by Ildong Pharmaceutical Co., Ltd., H2 2015 247
Ovarian Cancer - Pipeline by IMMD Inc., H2 2015 248
Ovarian Cancer - Pipeline by Immune Design Corp., H2 2015 249
Ovarian Cancer - Pipeline by ImmunoFrontier, Inc., H2 2015 250
Ovarian Cancer - Pipeline by ImmunoGen, Inc., H2 2015 251
Ovarian Cancer - Pipeline by Immunomedics, Inc., H2 2015 252
Ovarian Cancer - Pipeline by Immunovaccine, Inc., H2 2015 253
Ovarian Cancer - Pipeline by Incyte Corporation, H2 2015 254
Ovarian Cancer - Pipeline by Inflection Biosciences Limited, H2 2015 255
Ovarian Cancer - Pipeline by Innate Immunotherapeutics Ltd, H2 2015 256
Ovarian Cancer - Pipeline by Innate Pharma SA, H2 2015 257
Ovarian Cancer - Pipeline by INSYS Therapeutics, Inc., H2 2015 258
Ovarian Cancer - Pipeline by Inventiva SAS, H2 2015 259
Ovarian Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H2 2015 260
Ovarian Cancer - Pipeline by Johnson & Johnson, H2 2015 261
Ovarian Cancer - Pipeline by Juno Therapeutics Inc., H2 2015 262
Ovarian Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2015 263
Ovarian Cancer - Pipeline by Komipharm International Co., Ltd., H2 2015 264
Ovarian Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015 265
Ovarian Cancer - Pipeline by Laboratoire HRA Pharma, H2 2015 266
Ovarian Cancer - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2015 267
Ovarian Cancer - Pipeline by LegoChem Biosciences, Inc, H2 2015 268
Ovarian Cancer - Pipeline by Lipocure Ltd., H2 2015 269
Ovarian Cancer - Pipeline by Lymphocyte Activation Technologies, S.A., H2 2015 270
Ovarian Cancer - Pipeline by Mabion SA, H2 2015 271
Ovarian Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H2 2015 272
Ovarian Cancer - Pipeline by MacroGenics, Inc., H2 2015 273
Ovarian Cancer - Pipeline by Mebiopharm Co., Ltd., H2 2015 274
Ovarian Cancer - Pipeline by Medestea Research & Production S.p.A., H2 2015 275
Ovarian Cancer - Pipeline by MediaPharma s.r.l., H2 2015 276
Ovarian Cancer - Pipeline by MedImmune, LLC, H2 2015 277
Ovarian Cancer - Pipeline by Medivation, Inc., H2 2015 278
Ovarian Cancer - Pipeline by MEI Pharma, Inc., H2 2015 279
Ovarian Cancer - Pipeline by Merck & Co., Inc., H2 2015 280
Ovarian Cancer - Pipeline by Merck KGaA, H2 2015 281
Ovarian Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2015 282

List of Figures

Number of Products under Development for Ovarian Cancer, H2 2015 64
Number of Products under Development for Ovarian Cancer - Comparative Analysis, H2 2015 65
Number of Products under Development by Companies, H2 2015 66
Number of Products under Investigation by Universities/Institutes, H2 2015 88
Comparative Analysis by Late Stage Development, H2 2015 91
Comparative Analysis by Clinical Stage Development, H2 2015 92
Comparative Analysis by Early Stage Products, H2 2015 93
Assessment by Monotherapy Products, H2 2015 384
Number of Products by Top 10 Targets, H2 2015 386
Number of Products by Stage and Top 10 Targets, H2 2015 386
Number of Products by Top 10 Mechanism of Actions, H2 2015 405
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 405
Number of Products by Top 10 Routes of Administration, H2 2015 424
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 424
Number of Products by Top 10 Molecule Types, H2 2015 426
Number of Products by Stage and Top 10 Molecule Types, H2 2015 426